All data are based on the daily closing price as of September 6, 2024
l
Lotus Pharmaceutical
1795.TW
8.64 USD
0.33
+3.97%
Overview
Last close
8.64 usd
Market cap
2.29B usd
52 week high
11.22 usd
52 week low
6.44 usd
Target price
13.58 usd
Valuation
P/E
18.0537
Forward P/E
N/A
Price/Sales
4.3123
Price/Book Value
3.9514
Enterprise Value
2.52B usd
EV/Revenue
4.7737
EV/EBITDA
11.7683
Key financials
Revenue TTM
528.67M usd
Gross Profit TTM
243.71M usd
EBITDA TTM
181.21M usd
Earnings per Share
0.48 usd
Dividend
N/A usd
Total assets
34.64B usd
Net debt
7.52B usd
About
Lotus Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally. Its product portfolio focuses on generics in the fields of oncology, cardiology, nephrology, women's health, anti-obesity, and central nervous system diseases. The company also provides over-the-counter products. In addition, it engages in retail of clinical machines; biotech technological consulting services; sale of pharmaceuticals and medicinal chemical products; marketing activities; market planning and business information services; and consultancy services on health management, health technology, and trading information services. Further, the company offers management consultancy services; pharmaceutical regulatory affairs project management, and data collection and agency services; healthcare consultancy services and operates as a contract research organization. The company has strategic partnership with NRX Pharmaceuticals. Lotus Pharmaceutical Co., Ltd. was incorporated in 1966 and is headquartered in Taipei City, Taiwan.